This study is being conducted at Massachusetts General Hospital (MGH) to explore whether adding psychedelic coaching can enhance the effects of ketamine or esketamine maintenance treatment in individuals with treatment-resistant depression (TRD). The investigators are currently enrolling participants who are receiving ongoing maintenance intravenous (IV) ketamine or intranasal esketamine (Spravato) treatment at the MGH Ketamine Clinic. Participation in the study will involve adding coaching sessions to your existing ketamine maintenance treatment.
Age 18 years or older at the time of informed consent/study enrollment.
Ability to understand and provide informed consent.
Fluent in English (spoken and written).
Willingness to have coaching sessions recorded via HIPAA-compliant MGB approved video-based platform.
Presence of an unstable medical condition, as determined by the study clinician.
Significant neurocognitive impairment that impairs with individual's ability to maintain ADLs and would interfere with study participation, per study clinician judgment.
Newly initiated psychotherapy within the past 3 months.
Any condition or circumstance that, in the judgment of the Principal Investigator, makes participation unsafe or unsuitable.
Massachusetts General Hospital
Lead sponsor
Fireside Project
Collaborator